Structure Therapeutics (NASDAQ:GPCR) Trading 8.3% Higher – Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price shot up 8.3% during mid-day trading on Wednesday . The company traded as high as $30.98 and last traded at $31.11. 414,883 shares traded hands during trading, a decline of 45% from the average session volume of 749,362 shares. The stock had previously closed at $28.71.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Price Performance

The stock has a 50 day simple moving average of $29.75 and a 200-day simple moving average of $35.44. The firm has a market cap of $1.72 billion, a PE ratio of -40.83 and a beta of -2.78.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of GPCR. GAMMA Investing LLC increased its position in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter valued at $40,000. Assetmark Inc. boosted its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the last quarter. Quarry LP bought a new stake in Structure Therapeutics in the 2nd quarter worth about $79,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.